{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023417","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.013995+00:00","generated_at":"2026-05-22T03:35:59.426009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InfuSystem Q1 revenue $34.7M (+9% YoY); Adj. EBITDA $6.3M (+64%)","bullets":["Net revenue $34.7M (+9% YoY); net loss narrowed to $0.3M ($0.01 loss per share) from $1.1M.","Adjusted EBITDA $6.3M (+64% YoY); margin expanded 6.2pp to 18.2%.","Patient Services revenue up 12% to $20.8M; Device Solutions up 4% to $13.9M.","FY 2025 guidance reaffirmed: revenue growth 8-10%; Adj. EBITDA margin high teens.","CEO transition: Richard DiIorio out; Carrie Lachance (COO) incoming; $1.0M severance accrued."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023417","json":"https://secwatch.observer/filing/0001628280-25-023417.json","markdown":"https://secwatch.observer/filing/0001628280-25-023417.md","text":"https://secwatch.observer/filing/0001628280-25-023417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025023417/0001628280-25-023417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025023417/infu-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:35:59.426009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}